

Our vision

Disrupting neuroscience
Give patients hope

We are convinced that NETRI’s expertise can bring hope to patients with neurological diseases
by inventing innovative and high-end technologies and services, that are not yet available on the market.
New and disruptive approaches can be invented, through :



the understanding



the modeling



the improvement of existing treatment, for the benefit of all patients

Our mission

at NETRI, we know that we can change the way neurological diseases are treated, by acting and thinking differently.

We are committed to

Increasing discoveries on the brain and neurology
Contributing to the invention of new, personalized, and relevant disruptive treatment approaches

Speeding up the market entry of these approaches
And finally, alleviating the suffering of patients and their relatives

Our strategic priorities

Our technology enables us to meet the needs of all patients with neurological disorders.
NETRI has chosen to focus on 2 major global diseases and epidemics :
Alzheimer’s and Parkinson’s diseases

The burden of neurological disorders continues to rise on a global scale. Accordingly, medical communities, patients, industries and governments will face increasing demand for new treatments, rehabilitation, and support services.

As populations are growing and aging, the prevalence of the Parkinson’s and Alzheimer’s diseases steeply increases.
We believe these major disabling neurological disorders need an urgent response and are therefore our top strategic investment priorities.

Our R&D programs

We are comited to continuously investing in research programs to

Develop new in vitro models and demonstrate their physiological relevance: neurofluidic models of Alzheimer’s and Parkison’s diseases and their injuries, degeneration of Lewy body, Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Lobar Degeneration (FLD), gut-brain axis and innervated epidermis
Develop Standard Operating Protocols (SOP) for human induced pluripotent stem cells (iPScs) and patient-derived iPSCs differentiated neurons in our neurofluidic devices
Develop the first in vitro differential diagnostic medical device for neurological troubles, in collaboration with Lyon’s Hospital
Seeking partners for joint development with pharmaceutical industrials

Our POSITION ON ANIMAL TESTING

We believe that the combination of patient-derived iPSCs and
neurofluidic technologies fully captures the human brain physiology.

Animal experiments have recognized limited predictivity on recreating human biology and have raised ethical issues over time. NETRI’s technologies provide new ways to improve drug development, toxicology studies and identify effective treatments for neurological disorders.

OUR PARTNERS

ACADEMIC PARTNERS